India, March 21 -- Shares of Biogen Inc. (BIIB) are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. Ltd. (ESALY.PK) said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab.
The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of Aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.
Biogen and Eisai said they decided to trials after results of a futility analysis conducted by an independent data monitoring committee indicated the trials were unlikely to meet th...